anonymous
Guest
anonymous
Guest
ive noticed a very worrying trend over the last 2 years that q is letting staff with tangible drug development knowledge or sponsor experience leave the organization. So of this is elective but a lot is forced. Does TP really beleive he can maintain a dominate position in the marketplace with just Accenture clones and other CRO execs. If so, he really is believing the his own (and the EC's) hype. With the significant changes happening across life science and healthcare he must be naive to think q can differentiate without rich /deep scientific and domain skill ...... Unfortunately the current leadership and bench are inadequate and arguably incompetent. TP if you read this..... Please throw out your dinner plate strategy and reinvest in science and drug development skills across the organization, not just move ineffective roles offshore and promote non-Pharma people who will destroy q.